# Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

> **NCT00149019** · PHASE2 · WITHDRAWN · sponsor: **Hadassah Medical Organization** · enrollment: 12 (estimated)

## Conditions studied

- Metastatic Solid Tumors

## Interventions

- **DRUG:** Cell therapy with bispecific antibodies

## Key facts

- **NCT ID:** NCT00149019
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 12 (ESTIMATED)
- **Why stopped:** the PI is no longer work at Hadassah
- **Last updated:** 2011-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149019, "Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00149019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*